A multi cancer screening platform for fast and accurate early stage cancer detec...
A multi cancer screening platform for fast and accurate early stage cancer detection from urine samples
Globally, more than 18 million people are diagnosed with cancer each year and this number is set to exceed 22 million by 2030. According to the World Health Organization (WHO), about 50% of cancer deaths could be avoided by enabli...
Globally, more than 18 million people are diagnosed with cancer each year and this number is set to exceed 22 million by 2030. According to the World Health Organization (WHO), about 50% of cancer deaths could be avoided by enabling early cancer detection. Unfortunately, the market is still lacking a general test, suitable for the whole population, for detecting any type of cancer before the presentation of symptoms. Current gold standard procedures are highly invasive and risky, specific for one cancer type, and highly expensive. These factors limit their adoption to suspected cancer cases – i.e., after the presentation of symptoms, delaying cancer diagnosis and contributing to the huge economic burden on healthcare systems.
To overcome this problem, MDB DIAGNOSIS GROUP LTD (‘MDBD’) has developed Cancersensing, a revolutionary accurate and rapid screening platform for early diagnosis of multiple cancers from a single urine sample. The platform includes a highly specific and sensitive test that measures cancer-related biomarkers present in the urine, and a diagnostic software suite powered by proprietary machine learning algorithms and reference databases. Cancersensing makes cancer detection in its early stage available to all, maximizing survival rates and quality of life for patients, and reducing treatment costs and the cancer-related economic and societal burden.
During the feasibility assessment, MDBD will establish a go-to-market strategy and a supply chain, and define further development plan. During the second phase of innovation project, MDBD will optimize the Cancersensing screening platform, and perform clinical validation activities with hospital partners in the EU to obtain regulatory approval for commercialization.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.